Loading stock…

Neogen Corporation (NEOG) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated today

Neogen Corporation

NEOGMarket cap $2.56BPrice $11.7

Country🇺🇸United States

SectorHealthcare

IndustryHealthcare Equipment

Makes food and animal safety tests that detect contamination, disease, and toxins before products reach your table. Its tests can spot a single bacterium in a truckload of food — the reason most global meat producers depend on it.

In Bastion Portfolios?

52W Return+99%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+2%4

Revenue Forecast

Rev CAGR (1y)+2%3

Rev CAGR (3y)+1%2

Rev CAGR (5y)+3%2

Earnings Forecast

EPS Growth Y+10%5

EPS Growth Y+2+29%8

EPS Growth Y+3+28%8

Quality

Margins

EBIT Margin-1%1

Net Income Margin-6%1

Free Cash Flow Margin6%4

Debt

Net Debt/EBITDA5.22

Efficiency

ROE-3%2

ROA-2%2

Earnings Stability22

GEAR+VERY WEAK3

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)741

P/E Ratio (Forward 3y)262

P/BV1.29

EV Multiples

EV/EBITDA Fwd183

EV/EBIT Fwd2681

Yield

Free Cash Flow Yield1.9%4

Dividend Yieldna–

Momentum

Short term

1 month return-2%7

3 month return+20%10

YTD return+68%10

Mid term

Price vs 52wHigh82%6

1 year return+73%10

Long term

3 year return-31%1

5 year return-72%1

Risk Shield

Price Risk

Beta1.04

Volatility58%2

Free Cash Flow

Free Cash Flow Margin6%4

Free Cash Flow Yield1.9%4

Quality

ROCE-0%2

Earnings Stability22

Net Debt/EBITDA5.22

02Growth

Is it actually growing, and how fast?

NEOGNeogen

Revenue FY26$870M

GROWTH RATING↗

WEAK17 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+2%4

Revenue, next 1Y+2%3

Revenue, next 3Y, CAGR+1%2

Revenue, next 5Y, CAGR+3%2

EARNINGS FORECAST▾SCORE

EPS growth, FY27E0%5

EPS growth, FY28E+29%8

EPS growth, FY29E+28%8

GROWTH ASSESSMENT

STRENGTHS

None flagged.

WATCH

Revenue grew 2%/yr over the last 3 years and is set to keep growing around 1%/yr.

WEAKNESSES

Growth is the weak spot here, trailing 83% of companies worldwide.

Revenue is set to grow 1%/yr over the next 3 years, behind most of the market.2/10

Over five years revenue is set to grow 3%/yr, behind 80% of companies worldwide.2/10

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Stalled Business

Growth is a weak point here. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

AVERAGE59 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-2%7

3-month return+20%10

YTD return+68%10

MID & LONG-TERM▾SCORE

% of 52-week high82%6

1-year return+73%10

3-year return-31%1

5-year return-72%1

MOMENTUM ASSESSMENT

STRENGTHS

It's up 73% over the past year, but 18% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (-2%), over three months (+20%) and so far this year (+68%).

WATCH

None flagged.

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-31% over three years and -72% over five), behind 90% of the market.

BOTTOM LINE

Early Turnaround

A poor multi-year track record but a sharp recent rally. Momentum is turning up, yet the trend is young and unproven — it needs follow-through to confirm rather than fade. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Neogen Corporation. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

NEOGNeogen

Revenue FY26$870M

GROWTH RATING↗

WEAK17 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+2%4

Revenue, next 1Y+2%3

Revenue, next 3Y, CAGR+1%2

Revenue, next 5Y, CAGR+3%2

EARNINGS FORECAST▾SCORE

EPS growth, FY27E0%5

EPS growth, FY28E+29%8

EPS growth, FY29E+28%8

GROWTH ASSESSMENT

STRENGTHS

None flagged.

WATCH

Revenue grew 2%/yr over the last 3 years and is set to keep growing around 1%/yr.

WEAKNESSES

Growth is the weak spot here, trailing 83% of companies worldwide.

Revenue is set to grow 1%/yr over the next 3 years, behind most of the market.2/10

Over five years revenue is set to grow 3%/yr, behind 80% of companies worldwide.2/10

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Stalled Business

Growth is a weak point here. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

AVERAGE59 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-2%7

3-month return+20%10

YTD return+68%10

MID & LONG-TERM▾SCORE

% of 52-week high82%6

1-year return+73%10

3-year return-31%1

5-year return-72%1

MOMENTUM ASSESSMENT

STRENGTHS

It's up 73% over the past year, but 18% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (-2%), over three months (+20%) and so far this year (+68%).

WATCH

None flagged.

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-31% over three years and -72% over five), behind 90% of the market.

BOTTOM LINE

Early Turnaround

04Value

Are you paying a fair price for it?

Stop guessing on Neogen Corporation. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community